Physician profile
Clay Grimes
NPI 1245636471
$10,307.28
in general payments reported to CMS, 2019-2025
21 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,167 · 2022: $1,781 · 2023: $2,318 · 2024: $2,259 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,171 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,170.90 |
| Education | $188.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,059.89 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,226.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,176.18 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Vanda Pharmaceuticals INC. | $952.27 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $797.83 | 2021-2025 | Trintellix |
| Lundbeck LLC | $705.60 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $674.74 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $584.80 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $497.43 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $312.77 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $220.77 | 2021-2025 | Caplyta |
| Eisai INC. | $180.91 | 2021-2022 | |
| Almatica Pharma LLC | $170.09 | 2021-2025 | Loreev Xr, Gralise |
| Bausch Health US, LLC | $140.10 | 2021-2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $136.61 | 2022-2023 | Sublocade |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $129.13 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $98.45 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $84.38 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $81.31 | 2021-2022 | |
| Neos Therapeutics, LP | $52.62 | 2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $24.70 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Grimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.